Insider Selling: Treace Medical Concepts, Inc. (NASDAQ:TMCI) Director Sells $286,364.00 in Stock

Treace Medical Concepts, Inc. (NASDAQ:TMCIGet Rating) Director Richard W. Mott sold 11,014 shares of the firm’s stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $26.00, for a total transaction of $286,364.00. Following the completion of the sale, the director now directly owns 1,250,000 shares of the company’s stock, valued at $32,500,000. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Treace Medical Concepts Price Performance

Shares of NASDAQ TMCI opened at $25.94 on Friday. Treace Medical Concepts, Inc. has a 1 year low of $12.48 and a 1 year high of $26.50. The firm has a 50-day moving average of $23.57 and a 200 day moving average of $21.63. The company has a debt-to-equity ratio of 0.85, a current ratio of 5.66 and a quick ratio of 4.92.

Treace Medical Concepts (NASDAQ:TMCIGet Rating) last issued its earnings results on Tuesday, November 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.06. The business had revenue of $33.06 million during the quarter, compared to analysts’ expectations of $30.10 million. Treace Medical Concepts had a negative net margin of 35.87% and a negative return on equity of 51.67%. Research analysts anticipate that Treace Medical Concepts, Inc. will post -0.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TMCI. William Blair Investment Management LLC purchased a new position in Treace Medical Concepts in the second quarter worth about $11,740,000. Perceptive Advisors LLC raised its holdings in Treace Medical Concepts by 70.2% in the third quarter. Perceptive Advisors LLC now owns 1,601,979 shares of the company’s stock worth $35,356,000 after buying an additional 660,787 shares during the last quarter. BlackRock Inc. raised its holdings in Treace Medical Concepts by 23.1% in the third quarter. BlackRock Inc. now owns 2,268,911 shares of the company’s stock worth $50,074,000 after buying an additional 425,350 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Treace Medical Concepts in the third quarter worth approximately $8,334,000. Finally, Kornitzer Capital Management Inc. KS bought a new stake in shares of Treace Medical Concepts in the second quarter worth approximately $4,172,000. 46.17% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on TMCI. BTIG Research raised their target price on shares of Treace Medical Concepts to $29.00 in a research report on Tuesday, November 15th. Morgan Stanley lifted their price target on shares of Treace Medical Concepts from $23.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, October 11th.

About Treace Medical Concepts

(Get Rating)

Treace Medical Concepts, Inc, an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement.

See Also

Insider Buying and Selling by Quarter for Treace Medical Concepts (NASDAQ:TMCI)

Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.